Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 5;9(8):1370–1378. doi: 10.1080/19420862.2017.1371382

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Results for vehicle and 50 mg/kg lapatinib (lap)-treated BT474 xenograft-bearing mice. (A) Representative coronal ⁸⁹Zr-mAb3481 HER3 PET scans, 6 days post tracer injection. (B) In vivo ⁸⁹Zr-mAb3481 tumor and blood pool uptake, 6 days post tracer injection, expressed as SUV_mean. (C) Ex vivo ⁸⁹Zr-mAb3481 and ¹¹¹In-mAb002 tumor uptake data, presented as %ID/g. (D) Ex vivo ⁸⁹Zr-mAb3481 and ¹¹¹In-mAb002 blood pool data, presented as % ID/g. (E) Tumor volumes during treatment, with * P <0.05 and ** P <0.01. (F) Ex vivo tissue analysis. HER3 immunohistochemical staining of tumor tissues. (G) HER3 Western blots of xenograft tumor lysates. Each band represents a tumor from a single mouse. Immunoreactive spots were quantified by densitometric analysis and normalized using anti-human GAPDH, normalized to vehicle.